---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016262"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:12:16.879559+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monopar Q1 net loss $2.6M, cash $54.6M; ALXN1840 NDA planned early 2026

## Summary
- Cash $54.6M as of March 31, 2025; expected runway through Dec 2026 for NDA and trials.
- Net loss $2.6M ($0.38/sh) vs $1.6M ($0.51/sh) YoY; R&D expense rose 70% to $1.643M.
- ALXN1840 data presented at EASL; NDA submission to FDA planned early 2026.
- MNPR-101-Zr and MNPR-101-Lu Phase 1 trials active in Australia; preclinical Ac-225 program advancing.
- G&A expense doubled to $1.578M, driven by stock option grants and higher personnel costs.

## SEC filing metadata
- accession: 0001437749-25-016262
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774925016262/0001437749-25-016262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774925016262/mnpr20250508_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016262
- JSON: https://secwatch.observer/filing/0001437749-25-016262.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016262.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.